At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Nov 12, 2026 at 07:15 ET
NervGen Pharma announced that the FDA granted Breakthrough Therapy designation to NVG-291 for chronic traumatic cervical motor-incomplete spinal cord injury, based on Phase 1b/2a CONNECT SCI data showing functional hand use improvements. The designation may expedite development and regulatory review, but does not guarantee approval.
- FDA granted Breakthrough Therapy designation for NVG-291 in chronic traumatic cervical motor-incomplete SCI
- Designation based on safety and efficacy data from Phase 1b/2a CONNECT SCI study
- Phase 3 RESTORE registrational study is enrolling, targeting ~150 participants in US and Canada
- NVG-291 is a first-in-class neuroreparative peptide targeting the CSPG-PTPσ pathway
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access